Oncternal Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONCT research report →
Range $28 – $28
Price Chart
About the company
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating cancer treatments for diseases where current medical options are insufficient. Its clinical-stage portfolio features zilovertamab, a humanized monoclonal antibody designed to bind to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule that works by inhibiting the biological activity of ETS-family transcription factor oncoproteins.
- CEO
- James B. Breitmeyer
- IPO
- 2004
- Employees
- 27
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on ONCT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.56M
- P/E
- -0.04
- PEG
- -0.00
- P/S
- 1.99
- P/B
- 0.05
- EV/EBITDA
- -2.16
- Div Yield
- 0.00%
- Gross Margin
- -3690.19%
- Op Margin
- -5313.89%
- Net Margin
- -5029.17%
- ROE
- 61.57%
- ROIC
- -131.57%
Latest fiscal year · YoY change
- Revenue
- $785.00K-47.3%
- Gross Profit
- $-28,968,000-2309.6%
- Op Income
- $-41,714,000
- Net Income
- $-39,479,000+9.0%
- EPS
- $-13.43+18.6%
- OCF Growth
- +12.4%
- FCF Growth
- +12.4%
- 52W High
- $10.61
- 52W Low
- $0.53
- 50D MA
- $0.53
- 200D MA
- $3.80
- Beta
- 1.36
- RSI (14)
- 25
- Avg Volume
- 62.27K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Oncternal said both clinical programs are advancing, with ONCT-534 nearing an initial data readout and ONCT-808 reopening for enrollment after protocol changes tied to a prior serious safety event.· May 9, 2024
- ONCT-534’s Phase I/II study is fully enrolled in the 300 mg cohort, with management expecting an initial clinical update in late Q2 2024 and more data later in 2024.
- ONCT-808 has reopened for enrollment after protocol amendments that added tighter safety monitoring, lower dosing, and eligibility changes following a grade 5 toxicity.
- Cash was $27 million at March 31, 2024, and management said that should fund operations into Q1 2025.
- First-quarter revenue was $0.6 million from NIH grants; operating expenses were $9.3 million and net loss was $8.4 million, or $2.83 per share.
- Management said the modified 808 eligibility criteria do not change the addressable market, and they remain encouraged by investigator and patient interest in both programs.
Oncternal reported first-quarter 2024 grant revenue of $0.6 million. Operating expenses were $9.3 million, including $1.4 million of noncash stock-based compensation; R&D expense was $6 million and G&A expense was $3.3 million. Net loss was $8.4 million, or $2.83 per share basic and diluted. As of March 31, 2024, the company had about $27 million in cash, cash equivalents and short-term investments, no debt, and said this was sufficient to fund operations into Q1 2025. For guidance, management expects initial ONCT-534 clinical data in the latter part of Q2 2024, additional ONCT-534 readouts in Q4 2024, an ONCT-808 clinical update in mid-2024, and additional ONCT-808 data in Q4 2024.
CEO James Breitmeyer emphasized that Oncternal is advancing two first-in-class oncology programs addressing significant unmet need. He highlighted enthusiasm from KOLs, investigators, and patients for ONCT-534, saying the drug may overcome prostate cancer resistance mechanisms to current AR pathway inhibitors. On ONCT-808, he framed the protocol changes as a response to a prior severe toxicity while stressing the team’s focus on improving safety and maintaining progress.
CFO Richard Vincent said revenue remains limited to NIH grant funding, which was $0.6 million in Q1 2024. He detailed $9.3 million of operating expenses, including $1.4 million of stock-based compensation, with $6 million in R&D and $3.3 million in G&A. He also noted $27 million in cash, cash equivalents and short-term investments, no debt, and a cash runway into Q1 2025, while reiterating the company is on track for key data milestones in both programs.
Analysts focused on how soon ONCT-534 could move to the 600 mg cohort and whether the Q2 update could show efficacy relative to published ARSI-switching data. Management said the 300 mg cohort has three patients, the DLT period is ongoing, the safety review committee is expected mid-month to month-end, and if all goes well they will escalate to 600 mg. On the 534 efficacy question, management argued the drug should address more resistance mechanisms than switching between existing ARSI drugs because it is active against ligand-binding-domain mutations and splice variants like AR-V7. Questions on ONCT-808 centered on response durability, the impact of protocol changes, and whether CD19-failed patients would be expanded in Phase II; management said they are encouraged by durability but are not giving details, and confirmed Phase II can expand to CD19 failures. On the safety changes, management said they removed bulky disease, lowered the upper age limit, and added more infection monitoring after a grade 5 toxicity.
The call suggested both programs are moving forward with concrete near-term catalysts: ONCT-534 is fully enrolled in the 300 mg cohort and management expects a Q2 data readout, while ONCT-808 is back open for enrollment. Management also expressed confidence that ONCT-534’s mechanism may address resistance pathways beyond standard ARSI switching, and said the 808 eligibility changes do not reduce the addressable market.
The main risk remains clinical: ONCT-808 previously had a grade 5 toxicity, and management is still working through safety mitigations and a DLT period. Financially, the company is still loss-making with only $27 million in cash and a runway into Q1 2025, so execution on upcoming data readouts matters. There is also still a lot to prove clinically for both assets, with management only promising initial or updated data rather than confirmed efficacy.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.5%
- Shares Outstanding
- 2.96M
- Float Shares
- 2.71M
of shares held by institutions
23 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 39.28K | 0 |
| Column Capital Advisors, LLC | 1.45K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 20, 24 | KISNER DANIEL L | other | 2,200 |
| Jun 20, 24 | CARTER MICHAEL G | other | 2,200 |
| Jun 20, 24 | Wills Robert James | other | 2,200 |
| Jun 20, 24 | LARUE WILLIAM R | other | 2,200 |
| Jun 20, 24 | HALE DAVID F | other | 3,300 |
| Jun 20, 24 | MAZANET ROSEMARY | other | 2,200 |
| Jun 20, 24 | THEUER CHARLES | other | 2,200 |
| Jun 20, 24 | DeSimone Jill | other | 2,200 |
| Apr 8, 24 | Wills Robert James | buy | 3,086 |
| Mar 28, 24 | Wills Robert James | buy | 6,914 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ONCT coverage
Recent articles, reports, and earnings notes.
No research on ONCT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ONCT report →Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
gurufocus.com · Jun 23
Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations
globenewswire.com · Jul 1
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
globenewswire.com · Mar 7
Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript
seekingalpha.com · Aug 10
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates
zacks.com · Aug 8
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
globenewswire.com · Aug 8
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
globenewswire.com · Aug 1
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
globenewswire.com · Jul 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.